Last updated: August 2, 2026
Merrem IV, the injectable meropenem product originally commercialized by AstraZeneca, is a mature hospital antibiotic with no meaningful branded exclusivity remaining in the United States. Its commercial value has shifted from brand pricing to generic volume, contract-manufacturing scale, hospital formulary access, and supply reliability. AstraZeneca does not report standalone Merrem IV revenue in current financial disclosures, so the product’s financial trajectory must be assessed through regulatory status, generic competition, hospital demand, and broader carbapenem market conditions.
What is Merrem IV and how is it used?
Merrem IV contains meropenem, a broad-spectrum carbapenem antibiotic administered intravenously. It is used for serious bacterial infections, including complicated intra-abdominal infections, bacterial meningitis, complicated skin and skin-structure infections, and other severe infections caused by susceptible organisms.
The U.S. product received FDA approval under NDA 050706 on June 21, 1996. The historical reference product was Merrem IV, marketed by AstraZeneca Pharmaceuticals LP. The product is supplied as a sterile powder for reconstitution, primarily in 500-mg and 1-g vials. Dosing varies by infection, organism, renal function, and patient age. [1]
Meropenem competes in the inpatient broad-spectrum antibiotic market with:
- Imipenem/cilastatin
- Piperacillin/tazobactam
- Cefepime
- Ceftazidime
- Ertapenem
- Ceftazidime/avibactam
- Meropenem/vaborbactam
- Imipenem/cilastatin/relebactam
Merrem IV differs from newer branded products because meropenem itself is a generic active ingredient. Newer products generally compete through beta-lactamase inhibition, activity against resistant organisms, dosing convenience, stewardship positioning, or hospital formulary differentiation.
When did Merrem IV lose exclusivity?
Merrem IV lost practical U.S. market exclusivity after expiration of the relevant meropenem patent estate and regulatory exclusivities. Generic meropenem injection products entered the U.S. market in the early 2010s, ending the product’s ability to sustain branded pricing.
| Milestone |
Approximate timing |
Commercial effect |
| FDA approval of Merrem IV |
June 21, 1996 |
Established the U.S. reference product |
| Original branded patent protection |
Expired during the 2010s |
Removed core composition and product barriers |
| Generic meropenem injection entry |
Early 2010s |
Initiated rapid price and share erosion |
| Mature generic competition |
2010s onward |
Shifted value to volume and supply execution |
| Current U.S. commercial position |
Mature generic market |
Limited branded pricing power |
Meropenem does not have the exclusivity profile of a recent specialty antibiotic. It has no active new-drug exclusivity that protects the original Merrem IV product from generic competition. The product’s commercial life is therefore determined by hospital purchasing economics rather than patent-based exclusivity.
What patents protect Merrem IV?
The original Merrem IV patent estate centered on meropenem and related carbapenem chemistry, pharmaceutical compositions, and manufacturing processes. The principal U.S. composition patent commonly associated with meropenem is U.S. Patent No. 5,583,219. That patent is expired and does not create a current barrier to routine generic meropenem injection.
Patent protection can still matter in three narrower areas:
- Manufacturing processes for meropenem or sterile injectable formulations.
- Formulation, stabilization, or reconstitution technology.
- New combinations or delivery systems containing meropenem.
Those rights do not restore exclusivity to ordinary meropenem for injection unless they are tied to a separately protected product or legally enforceable method of use.
What formulations are protected by Merrem IV patents?
The core Merrem IV presentation is a conventional sterile powder for intravenous reconstitution. Its commercial protection was not based on a durable delivery platform comparable to long-acting injectables, liposomal formulations, or device-enabled products.
Generic manufacturers can generally compete with equivalent meropenem injection products if they satisfy FDA requirements for pharmaceutical equivalence, bioequivalence where applicable, sterility, potency, stability, and manufacturing quality. Formulation patents may create narrow barriers, but they do not generally protect the basic meropenem injectable market after expiration of the original product patents.
What is the Orange Book status of Merrem IV?
The FDA Orange Book historically listed Merrem IV under NDA 050706. The relevant product is an injectable meropenem reference product, not a biologic. Accordingly, biosimilar regulations do not apply.
The commercial importance of the Orange Book listing is limited because the foundational product and patent protections have expired. Generic applicants could rely on an abbreviated new drug application pathway and challenge listed patents through Paragraph IV certifications when applicable.
The Orange Book remains relevant for:
- Identifying the reference listed drug.
- Reviewing listed patents and exclusivity information.
- Confirming the regulatory basis for generic approvals.
- Tracking whether patents remain listed against a specific presentation.
The Orange Book does not measure current market share, net pricing, hospital purchasing contracts, or supply reliability. Those factors are more important than the historical listing for current Merrem IV economics. [2]
Which companies compete with Merrem IV?
Meropenem supply is divided among generic injectable manufacturers, contract manufacturers, and hospital-distributor channels. The competitive field can change by presentation, country, tender award, and shortage status.
Key competitive categories include:
| Competitive category |
Examples |
Effect on Merrem IV economics |
| Generic meropenem |
Multiple FDA-approved manufacturers |
Drives price compression |
| Other carbapenems |
Imipenem/cilastatin, ertapenem |
Limits formulary concentration |
| Broad-spectrum beta-lactams |
Piperacillin/tazobactam, cefepime |
Substitutes in many empiric regimens |
| Newer beta-lactam combinations |
Vabomere, Avycaz, Recarbrio |
Capture resistant-organism use at premium prices |
| Stewardship-driven alternatives |
Narrower agents selected after cultures |
Reduce prolonged meropenem exposure |
The most important competitive distinction is between routine empiric use and treatment of multidrug-resistant infections. Meropenem remains valuable for serious gram-negative infections, but antimicrobial stewardship programs often restrict carbapenem use to preserve activity and reduce resistance pressure.
How strong is the Merrem IV patent estate?
The current patent estate is weak as a commercial barrier because the core patents are expired and the product is widely substitutable through generic injection products.
| Patent-estate factor |
Current assessment |
| Core active ingredient protection |
Expired |
| New-drug exclusivity |
Expired |
| Generic substitution barrier |
Low |
| Formulation differentiation |
Limited |
| Device or delivery-platform protection |
Not central to Merrem IV |
| Manufacturing complexity |
Moderate to high |
| Regulatory switching cost |
Low to moderate |
| Supply-chain barrier |
Material |
The principal residual barrier is technical manufacturing quality. Sterile injectable production requires validated aseptic processing, reliable active pharmaceutical ingredient supply, quality-control testing, and regulatory compliance. These requirements can restrict the number of dependable suppliers, but they do not provide the patent-based pricing power associated with a protected branded product.
What generic entry risks exist for Merrem IV?
Generic entry risk is already realized rather than prospective. The principal current risk is not a new Paragraph IV launch against Merrem IV. It is continued price erosion, hospital substitution, and procurement displacement among existing generic suppliers.
Generic-market risks include:
- Lower average selling prices during competitive tenders.
- Contract losses when hospitals consolidate purchasing.
- Reduced demand if stewardship programs favor narrower agents.
- Shortages caused by manufacturing interruptions or limited sterile capacity.
- Substitution toward newer agents for resistant pathogens.
- Margin pressure from distributor and group-purchasing-organization negotiations.
For generic manufacturers, the product remains commercially viable because it is a high-need hospital antibiotic. Its value depends on production reliability and low-cost scale rather than premium positioning.
What is the financial trajectory for Merrem IV?
AstraZeneca’s public financial reporting does not provide standalone current revenue, gross margin, or operating-profit figures for Merrem IV. The product is not reported as a separately material growth brand in the company’s current portfolio disclosures. Its financial trajectory is therefore best characterized as a transition from branded pharmaceutical revenue to mature generic-market economics.
Branded phase
During the branded phase, Merrem IV benefited from:
- Patent-protected pricing.
- Hospital demand for broad-spectrum intravenous therapy.
- Limited direct substitution.
- Established clinical familiarity.
- Use in severe infections requiring inpatient treatment.
Generic erosion phase
After generic entry, branded revenue would have been pressured by:
- Mandatory or encouraged generic substitution.
- Hospital tender competition.
- Lower generic acquisition costs.
- Declining branded formulary preference.
- Reduced reimbursement differentiation.
Mature-market phase
The current value pool is distributed among generic manufacturers, wholesalers, hospital systems, and purchasing organizations. Revenues are driven by unit volume, not by brand premium.
| Financial driver |
Current direction |
| Unit demand |
Stable to moderately variable |
| Branded price |
Structurally weak |
| Generic price |
Competitive and tender-sensitive |
| Gross margin |
Dependent on manufacturing scale |
| Revenue growth |
Limited without geographic or contract expansion |
| Shortage-related pricing |
Can increase temporarily |
| Long-term growth |
Tied to hospital utilization and resistance patterns |
Meropenem demand can increase during outbreaks, higher-acuity hospital admissions, or periods of elevated antimicrobial resistance. Those increases do not necessarily translate into durable manufacturer revenue because additional suppliers can enter or hospitals can shift to competing beta-lactams.
How does Merrem IV compare with Vabomere?
Merrem IV and Vabomere are not equivalent commercial products.
| Attribute |
Merrem IV |
Vabomere |
| Active ingredients |
Meropenem |
Meropenem plus vaborbactam |
| Product type |
Mature generic/reference antibiotic |
Branded combination product |
| Primary positioning |
Broad-spectrum carbapenem therapy |
Selected resistant gram-negative infections |
| Patent profile |
Core protection expired |
Combination and related patent protection may remain relevant |
| Pricing |
Generic |
Premium branded |
| Main commercial risk |
Price and supply competition |
Reimbursement, adoption, and patent risk |
| FDA pathway |
Original NDA and generic ANDAs |
New drug application for combination product |
Vabomere can command a higher price because vaborbactam expands activity against certain beta-lactamase-producing organisms. The products compete clinically in some resistant-infection settings, but Vabomere is not a direct replacement for all Merrem IV use.
What patent litigation and Paragraph IV challenges affect Merrem IV?
The main patent litigation risk associated with the original Merrem IV product occurred during the generic-entry period. The current commercial market is not defined by active litigation over the basic meropenem injection product.
Paragraph IV certifications may have been used by generic applicants against listed patents during the original abbreviated-approval process. Once the core listed patents expired and multiple generic suppliers entered, litigation ceased to be the central market variable.
Current legal exposure is more likely to arise from:
- Manufacturing-process patents.
- Formulation or stability claims.
- New meropenem combinations.
- Contract disputes.
- Quality-related regulatory enforcement.
- Patent litigation involving newer beta-lactamase inhibitor products.
What is the FDA regulatory status of Merrem IV?
Meropenem injection is an FDA-approved antibacterial drug administered intravenously. Generic versions must meet requirements covering identity, strength, quality, purity, sterility, labeling, and manufacturing controls.
The major regulatory risks are operational:
- FDA inspection findings at sterile manufacturing sites.
- Product recalls.
- Supply interruptions.
- Changes in approved manufacturing facilities.
- Drug-shortage listing or allocation constraints.
- Failure to maintain validated aseptic processes.
For a mature injectable antibiotic, regulatory execution can influence market share more than patent ownership. A manufacturer with reliable supply may retain hospital contracts even when several technically substitutable products are approved.
What geographic markets matter for Merrem IV?
Meropenem is sold across the United States, Europe, Japan, emerging markets, and hospital systems in other regulated and semi-regulated jurisdictions. Patent expiry and generic entry occurred on different schedules by country, producing uneven pricing and competition.
Geographic economics depend on:
- National tender systems.
- Hospital reimbursement.
- Local generic approval standards.
- Import and manufacturing capacity.
- Antimicrobial-resistance prevalence.
- Government procurement policy.
- Currency and raw-material costs.
The United States has a fragmented hospital purchasing market but strong generic substitution. European markets often rely more heavily on national or regional tenders. Emerging markets may show higher unit growth but lower prices and greater exposure to local manufacturing and procurement conditions.
What manufacturing and intellectual-property barriers remain?
Meropenem is not a simple oral solid-dose product. It requires sterile injectable manufacturing and controlled handling of a beta-lactam antibiotic. Manufacturing barriers include:
- Reliable supply of high-quality meropenem API.
- Aseptic filling and validated sterilization controls.
- Stability protection during storage.
- Container-closure integrity.
- Contamination controls for beta-lactam facilities.
- Regulatory qualification of multiple sites.
- Inventory planning for hospital demand.
These barriers can support temporary supplier pricing during shortages. They do not recreate the long-term exclusivity that Merrem IV had before generic entry.
Key Takeaways
- Merrem IV is the original meropenem intravenous product and received FDA approval in 1996.
- Its core patent and regulatory exclusivity have expired.
- Generic entry transformed Merrem IV from a branded-margin product into a volume-driven hospital antibiotic.
- AstraZeneca does not publicly disclose standalone current Merrem IV revenue.
- Current economics depend on generic price competition, hospital tenders, manufacturing reliability, and antimicrobial stewardship.
- The main commercial barrier is sterile injectable manufacturing, not active patent protection.
- Vabomere and other newer beta-lactam combinations compete in selected resistant-infection segments but have different patent and pricing profiles.
- Current Paragraph IV and Orange Book issues are secondary to supply, contracting, and formulary dynamics.
- The product remains clinically important but has limited branded revenue-growth potential.
FAQs
Does AstraZeneca still own the commercial value of Merrem IV?
AstraZeneca historically owned and marketed the reference product, but the commercial value of ordinary meropenem injection is now concentrated in generic manufacturers and hospital procurement channels.
Is Merrem IV a biologic eligible for biosimilar competition?
No. Merrem IV is a small-molecule injectable antibiotic. Generic competition proceeds through the abbreviated new drug application pathway, not the biosimilar pathway.
Can a generic manufacturer still obtain patent protection for meropenem?
A manufacturer may obtain patents on a genuinely novel manufacturing process, formulation, combination, or delivery system. Such patents would not generally restore exclusivity to conventional meropenem injection.
Why can meropenem prices rise after patent expiry?
Prices can rise temporarily when sterile manufacturing capacity is constrained, a supplier has a quality problem, API supply is disrupted, or hospitals face a shortage. These increases are usually supply-driven rather than patent-driven.
Does antimicrobial resistance increase Merrem IV revenue?
Resistance can increase use of meropenem in selected infections, but stewardship restrictions, generic price competition, substitution by newer agents, and hospital tendering can prevent higher utilization from producing proportional revenue growth.
References
-
U.S. Food and Drug Administration. (1996). Merrem IV (meropenem for injection) prescribing information, NDA 050706. FDA Drugs@FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (n.d.). Meropenem injection drug labels. DailyMed.
-
U.S. Patent and Trademark Office. (1996). U.S. Patent No. 5,583,219, carbapenem antibiotics. USPTO Patent Center.
-
AstraZeneca PLC. (2024). Annual report and form 20-F 2023. AstraZeneca.
-
U.S. Food and Drug Administration. (n.d.). Drug shortages: Meropenem for injection. FDA Drug Shortages Database.
